BioLineRx is a clinical-stage biopharmaceutical development company with a focus on oncology. Co.'s development and commercialization pipeline consists of two clinical-stage therapeutic candidates: BL-8040, a peptide for the treatment of hematological malignancies, solid tumors and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, Co. has a therapeutic product called BL-5010 for the treatment of skin lesions. The BLRX stock yearly return is shown above.
The yearly return on the BLRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BLRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|